2. Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage
  3. Drug-Linker Conjugates for ADC Topoisomerase
  4. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer.

For research use only. We do not sell to patients.

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan Chemical Structure

CAS No. : 2578019-72-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan Related Antibodies

Top Publications Citing Use of Products

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms
Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents Dual payloads

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II DNA gyrase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer[1].

IC50 & Target

Camptothecins

 

In Vitro

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (1 nM - 1 μM; 72 h) inhibits proliferation of Fadu, Bxpc-3, A431, and SW620 human tumor cell lines in vitro with IC50 values ranging from 12.44 nM to 242.09 nM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Fadu, Bxpc-3, A431, SW620 human tumor cell lines
Concentration: 1 nM - 1 μM (5-fold serial dilutions, 9 concentrations total)
Incubation Time: 72 h
Result: Inhibited proliferation of Fadu cells with an IC50 of 12.44 nM.
Inhibited proliferation of Bxpc-3 cells with an IC50 of 242.09 nM.
Inhibited proliferation of A431 cells with an IC50 of 27.86 nM.
Inhibited proliferation of SW620 cells with an IC50 of 221.24 nM.
In Vivo

C-11 (10 mg/kg; intravenous injection; administered on days 0, 7, 14 and 21) achieves significant tumor growth inhibition in A431 tumor-bearing BALB/c nude mice, with an average tumor volume of 347.2 mm3 on day 20, and exhibits favorable in vivo safety through stable body weight[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice (4~6 weeks old)[1]
Dosage: 10 mg/kg
Administration: i.v.; on days 0, 7, 14, 21
Result: Reduced average tumor volume to 347.2 mm3 on day 20, compared to 1526.5 mm3 in the blank control group.
Increased average body weight from 17.6 g on day 0 to 20.1 g on day 20.
Showed no significant weight loss or mouse mortality during the study.
Molecular Weight

1074.12

Formula

C55H60FN9O13
CAS No.
SMILES

O=C(C1CCC(CC1)CN2C(C=CC2=O)=O)NCC(NCC(N[C@@H](CC3=CC=CC=C3)C(NCC(NCO[C@@H](C)C(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan2578019-72-2Drug-Linker Conjugates for ADCTopoisomerasea431 tumorhuman tumor cell linesSW620Bxpc-3BALB/c nude miceA431FaduInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan
Cat. No.:
HY-153067
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.